If the owned on the record date and sold it before the ex-dividend date their broker will forward the shares to the new owner of those shares. END OF STORY! Stop perpetuating the nonsense.
The people that say "For those of you who are saying post-5/28 buyers DON'T get Asterias" are just plain wrong.
You will get Asterias shares. It will take longer because Geron will send them to the brokerage account of someone that sold their GERN shares and then that broker will forward them on.
The ex-date is the date on which the stock begins to trade minus the asset that was distributed .. cash or in this case shares. The record date is the date which the company identifies who will get the asset. If someone on the list no longer owns the shares it's up to the brokers to sort it out.
HA HA HA HA.... I was right. LMFAO!
"In order to receive shares of Asterias Series A common stock or cash in the series A Distribution,Geron stockholders as of the Record Date must hold their shares of Geron common stock THROUGH THE EX-DIVIDEND DATE,which will be determined by Nasdaq
That's not the way it works with dividends. The record date provides a list of shareholders for which the company is responsible for delivering the dividend. If you own a $10 on the record date you will get the dividend. However, if you sell prior to the ex-dividend date you will have to fork over the dividend. On the ex-dividend date the stock will open @ $9 if it closed @ $10 the day before. So those that bought the stock between the record date and the exdividend date will have a $1 dividend and a $9 stock. That's the only fair way to do it and if it wasn't done this was nobody would buy a stock between the record date and the ex-dividend date because they would get screwed.
If may be different for this spin-off but Geron's PPS did not trade differently after the record date so I expect that the ex-dividend date is all that matters as far as who ultimately gets the shares. Perhaps it didn't trade differently because the Asterias shares were viewed as having little or no value.
... And have been trading/investing for 35 years.
There is a webinar available online given by the lead investigator Dr. Hoffman at Tufts. He said the indications they chose (7 of them) were chosen because the diseases have human parallels. Their goal is to not only develop treatments for animals but also to lay the groundwork to launch human INDs based on the results. He feels that their approach of treating animals (peoples real pets) with naturally occurring diseases provides better indications of efficacy than does testing on rodents that are engineered to have particular diseases. So even though they are performing vet trials they are very focused on the human application of the therapy.
Just think, if human cells work well in dogs they'll probably even work better in humans.
Perhaps it's just someone making fun of a right wing nut job that spams a biotech stock message board with right wing garbage. Can you say loooooser?
Go easy on the resident multi-aliases STEM pumper. What he lacks in brain power he tries to make up for in his persistent spamming of pump messages.
This is an important question. If it doesn't work better than a commercially available food dye then they will make not make money on PV-10. They would be competing with a food dye.
The "naked shorts" conspiracy. That's one of the Yahoo message board's classics.
Another good one is "the MMs lowering the price so the Big Boys can get in cheap"
Wondering if PVCT compared the two.
ACT already has financed with Lincoln. This deal looks to be about the same.
ISCO is down to a market cap of $12 million and it doesn't look like they have the funds to file an IND. ACTC has a market cap of $220 million and just hired a top notch CEO. ISCO's issues aren't related to Lincoln.
I will side with the hedge fund as opposed to a message board clown.